CP-10 (Ipamorelin / CJC-1295)

What is CP-10?

CP-10 is a research-grade combination blend of CJC-1295 (No DAC) and Ipamorelin in a single vial. CJC-1295 (No DAC), also known as Modified GRF(1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH) with 29 amino acids. Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist. Together, they target complementary pathways — GHRH receptor and GHS receptor — and have been studied for synergistic effects on growth hormone release in preclinical models.

Research Applications

• Synergistic GH Secretion: Preclinical research demonstrates that co-administration of a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) produces greater GH release than either compound alone, through dual receptor activation.

• Pulsatile GH Release Studies: Ipamorelin preserves the natural pulsatile pattern of GH release, making this combination valuable for studying physiological vs. supraphysiological GH secretion profiles.

• Selectivity Research: Ipamorelin is one of the most selective GH secretagogues studied — it does not significantly affect cortisol, prolactin, or ACTH levels, making this blend useful in controlled endocrine research.

• Receptor Pharmacology: The combination allows researchers to study GHRH-R and GHS-R1a cross-talk and downstream signaling convergence on somatotroph cells.

Compound Information

• CJC-1295 (No DAC): Modified GRF(1-29), MW 3,367 Da

• Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2, MW 711.9 Da

• Blend Ratio: 1:1 by weight (5mg CJC + 5mg Ipamorelin per 10mg vial)

• Appearance: White lyophilized powder

• Solubility: Reconstitute with sterile water or bacteriostatic water

Specifications

• Purity: >99% per component (HPLC verified)

• Form: Lyophilized powder

• Container: Sealed vial (3mL flip-top)

• Storage: -20°C or below, protected from light

• Shelf Life: 2+ years when stored properly

• Certificate of Analysis available on request

Peer-Reviewed References

• Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006.

• Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998.

• Jimenez-Reina L, et al. "Interaction of growth hormone-releasing peptides with the GH neuroendocrine axis." Endocrine. 2002.

• Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Ann Intern Med. 2008.

For research use only. Not for human consumption. All products are sold strictly for laboratory and research purposes.